KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other financing activities (2020 - 2022)

Halozyme Therapeutics (HALO) has disclosed Other financing activities for 3 consecutive years, with $639000.0 as the latest value for Q4 2022.

  • Quarterly Other financing activities changed N/A to $639000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $4.9 million for FY2025, N/A changed from the prior year.
  • Other financing activities for Q4 2022 was $639000.0 at Halozyme Therapeutics, down from $6.0 million in the prior quarter.
  • The five-year high for Other financing activities was $6.0 million in Q2 2022, with the low at -$68000.0 in Q2 2020.
  • Average Other financing activities over 3 years is $1.2 million, with a median of $234000.0 recorded in 2020.
  • The sharpest move saw Other financing activities skyrocketed 135.29% in 2021, then soared 24912.5% in 2022.
  • Over 3 years, Other financing activities stood at -$68000.0 in 2020, then surged by 135.29% to $24000.0 in 2021, then surged by 2562.5% to $639000.0 in 2022.
  • According to Business Quant data, Other financing activities over the past three periods came in at $639000.0, $6.0 million, and $24000.0 for Q4 2022, Q2 2022, and Q2 2021 respectively.